Bemarituzumab

Bemarituzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	FGFR2
Clinical data
ATC code	none
Identifiers
CAS Number	1952272-74-0

Bemarituzumab (INN^[1]) is a monoclonal antibody that is being investigated for gastroesophageal junction adenocarcinoma.

This drug is being developed by Five Prime Therapeutics, Zai Lab Limited. As of 2018, bemarituzumab is undergoing Phase III trials.

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab^§ Ascrinvacumab^§ Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin^† Enoticumab^§ Figitumumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Teprotumumab^† Tovetumab^§ Vantictumab^§ Vesencumab^§ Votumumab^§ Zalutumumab^† "-melu-" (melanoma) Flanvotumab^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox^† Naptumomab estafenatox Nofetumomab merpentan Omburtamab Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab^† Loncastuximab tesirine Margetuximab^† Rituximab^# Siltuximab Ublituximab^† "-mexi-" (melanoma): Ecromeximab^§
Humanized ("-tuzu-")	Abituzumab^§ Alemtuzumab Bemarituzumab^† Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab^§ Emibetuzumab^§ Enoblituzumab^§ Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin^‡ Imgatuzumab^§ Inotuzumab ozogamicin^† Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin^† Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan^† Sibrotuzumab^§ Simtuzumab^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§
Veterinary ("-tuvet-")	Blontuvetmab^§ Tamtuvetmab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.